纽祺（上海）健康科技有限公司

Like many other companies, Polyplus-transfection has anticipated and have taken substantial precautions to minimize any potential impact of the COVID-19 situation to our employees and customers. As a business continuity plan, Polyplus is taking actions to protect employees, to assure supply and to be able to fulfill demands.

Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, today announces it will make available to the market a novel transfection reagent FectoVIR®-AAV in May 2020. The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.

Polyplus-transfection® SA, the leading biotechnology company that supports gene and cell therapy by supplying innovative transfection solutions, today announces the availability of the first GMP-grade transfection reagent PEIpro®-GMP in additional conditioning that will ensure additional flexibility and cost-efficiency.